Literature DB >> 18924105

Proteomic analysis of conditioned media from glucose responsive and glucose non-responsive phenotypes reveals a panel of secreted proteins associated with beta cell dysfunction.

Paul Dowling1, William Shields, Sweta Rani, Paula Meleady, Michael Henry, Per Jeppesen, Lorraine O'Driscoll, Martin Clynes.   

Abstract

Media conditioned by dysfunctioning pancreatic beta cells offer an excellent source of potential protein markers associated with this phenotype. Proteins identified from cell culture model systems are often found to be of importance clinically. Previous work by us and others have shown that low-passage MIN-6 cells (MIN-6(L)) respond to changes in glucose concentrations, producing an approximately 5.5-fold glucose-stimulated insulin secretion (GSIS) in response to 26.7 mmol/L, compared with 3.3 mmol/L, glucose. After continuous culture or high-passage (MIN-(H)), this GSIS was no longer present and thus represents an excellent model system for investigating beta cell dysfunction. Employing 2-D difference gel electrophoresis and mass spectrometry a panel of protein markers were identified in conditioned media (CM) from MIN-6(L) and MIN-6(H) beta cells. These proteins, including secretogranin II, secretogranin III and transthyretin, are associated with secretory granule biogenesis and were found to have substantially increased levels in the CM from the non-responsive high-passage MIN-6 beta cells. A panel of protein markers found to have increased abundance levels in CM from MIN-6(H) compared with MIN-6(L) beta cells may have the potential to be used clinically for assessing beta cell function and to monitor the effects of specific therapeutics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18924105     DOI: 10.1002/elps.200800152

Source DB:  PubMed          Journal:  Electrophoresis        ISSN: 0173-0835            Impact factor:   3.535


  8 in total

1.  Systematic proteomic analysis identifies β-site amyloid precursor protein cleaving enzyme 2 and 1 (BACE2 and BACE1) substrates in pancreatic β-cells.

Authors:  Ina Stützer; Nathalie Selevsek; Daria Esterházy; Alexander Schmidt; Ruedi Aebersold; Markus Stoffel
Journal:  J Biol Chem       Date:  2013-02-19       Impact factor: 5.157

2.  Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma.

Authors:  Jiong Chen; Long-Jiang Chen; Yun-Lian Xia; Hang-Cheng Zhou; Ren-Bao Yang; Wen Wu; Yin Lu; Li-Wei Hu; Yue Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-02       Impact factor: 4.553

Review 3.  Secretogranin III: a diabetic retinopathy-selective angiogenic factor.

Authors:  Wei Li; Keith A Webster; Michelle E LeBlanc; Hong Tian
Journal:  Cell Mol Life Sci       Date:  2017-08-30       Impact factor: 9.261

Review 4.  Transthyretin: the servant of many masters.

Authors:  Joel N Buxbaum; Natàlia Reixach
Journal:  Cell Mol Life Sci       Date:  2009-07-31       Impact factor: 9.261

5.  Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy.

Authors:  Michelle E LeBlanc; Weiwen Wang; Xiuping Chen; Nora B Caberoy; Feiye Guo; Chen Shen; Yanli Ji; Hong Tian; Hui Wang; Rui Chen; Wei Li
Journal:  J Exp Med       Date:  2017-03-22       Impact factor: 14.307

6.  Serum Secretogranin III Concentrations Were Increased in Subjects with Metabolic Syndrome and Independently Associated with Fasting Plasma Glucose Levels.

Authors:  Chun-Chung Lin; Kai-Pi Cheng; Hao-Chang Hung; Chung-Hao Li; Ching-Han Lin; Chih-Jen Chang; Che-Yuan Hu; Hung-Tsung Wu; Horng-Yih Ou
Journal:  J Clin Med       Date:  2019-09-11       Impact factor: 4.241

7.  The Latest Insights into Adipokines in Diabetes.

Authors:  Won Kon Kim; Kwang-Hee Bae; Sang Chul Lee; Kyoung-Jin Oh
Journal:  J Clin Med       Date:  2019-11-05       Impact factor: 4.241

8.  Microarray analysis of novel candidate genes responsible for glucose-stimulated insulin secretion in mouse pancreatic β cell line MIN6.

Authors:  Eiji Yamato; Fumi Tashiro; Jun-ichi Miyazaki
Journal:  PLoS One       Date:  2013-04-03       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.